ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
55 announcements with these filters
Lupin Limited announced that the acquisition of minority shareholding in Multicare Pharmaceuticals Philippines is ongoing. Completion is now expected in July 2026, pending closing conditions.
Lupin shared positive Phase 1 trial results for its novel SOS1 inhibitor, LNP8701, at ASCO 2026. The drug demonstrated safety and favorable anti-tumor activity in metastatic patients.
Lupin received Chinese regulatory approval for Oseltamivir Phosphate Oral Suspension, marking its first product entry into China. This milestone strengthens its global footprint in paediatric care.
Lupin Limited filed its Annual Secretarial Compliance Report for FY2026. The report by Makarand M. Joshi & Co. confirms regulatory adherence with no major non-compliances noted.
Lupin debuted in the Dow Jones Best-in-Class Indices for 2026. This prestigious inclusion recognizes the company's industry-leading ESG performance and sustainability leadership.
Lupin received tentative U.S. FDA approval for Revefenacin Inhalation Solution, targeting a USD 260.7 million market. This strengthens Lupin's respiratory portfolio in the United States.
Lupin reported record FY26 revenues of ₹27,958 cr (up 23%) and EBITDA of ₹8,160 cr (up 55%). Management focuses on complex products and India prescription growth.
Lupin received US FDA approval for Famotidine Injection, targeting an $8.7 million market. This ₹82.65 Crore opportunity strengthens its presence in the US gastrointestinal segment.
Lupin delivered a record-breaking FY26 with 32% revenue growth and 68% EBITDA surge, driven by US generic exclusivity and robust India prescription growth.
Lupin Limited recommended a final dividend of ₹18 per equity share for FY 2026. This 900% payout remains subject to shareholder approval at the AGM.
Lupin recommended appointing Deloitte Haskins & Sells as Statutory Auditors for five years. This follows the tenure completion of current auditors B S R & Co. LLP.
Lupin reported strong Q4 FY26 results with sales reaching ₹73,919 mn, up 33% YoY, driven by a 55% surge in North American markets.
Lupin reported FY2026 sales of ₹27487.50 Crore, reflecting 23.9% annual growth. Strong performance in U.S. and India markets drove significant margin expansion and profitability.
Lupin Limited recommended appointing Deloitte Haskins & Sells as Statutory Auditors for a five-year term. This regulatory move follows the term completion of existing auditors.
Lupin Ltd reported revenue from operations of ₹7,475 Cr (+31.9% YoY) and net profit of ₹1,469 Cr (+87.7% YoY) for Q4 FY26.
Lupin Ltd reported annual consolidated revenue of ₹27,958 Crore and recommended a final dividend of ₹18 per share. This performance marks significant growth and shareholder returns.
Lupin Limited received U.S. FDA approval for Glycerol Phenylbutyrate Oral Liquid, a bioequivalent version of Ravicti. The reference product had annual U.S. sales of approximately ₹3201.50 Crore (USD 337 million) in 2025. The drug is indicated for chronic management of urea cycle disorders, strengthening Lupin's specialty generic portfolio in the U.S. market.
Lupin Limited allotted 36,752 fully paid-up equity shares of ₹2 each under its Employee Stock Option plans on May 4, 2026. This allotment increases the company's paid-up share capital to ₹91.44 Crore, consisting of 45,72,15,863 equity shares.
Lupin Limited has launched Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States. This follows approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA). The product is a generic version of Xigduo XR, expanding Lupin's anti-diabetic portfolio in the U.S. market.
Lupin Ltd announced the conclusion of a U.S. FDA inspection at its Somerset, New Jersey facility. The inspection, held from April 13-17, 2026, resulted in a Form-483 with three observations. The company plans to address these observations within the stipulated timeframe and remains committed to CGMP standards.
Lupin Limited incorporated a wholly owned subsidiary, Lupin (Thailand) Limited, on April 17, 2026. The new entity, based in Thailand, will focus on importing, marketing, and distributing pharmaceutical products. It has an initial paid-up capital of 3,000,000 Baht, entirely held by the parent company.
Lupin's US subsidiary, LPI, entered a USD 30 million (₹279 Crore) settlement agreement with Humana Inc. to resolve antitrust litigation in Philadelphia. Lupin denies all allegations of anticompetitive behavior. The settlement amount was already accounted for in prior financial results, ensuring no fresh impact on consolidated earnings.
Lupin Limited has launched Dapagliflozin Tablets (5 mg and 10 mg) in the United States. The product is a bioequivalent generic version of Farxiga®, following approval from the U.S. FDA. This launch expands Lupin's anti-diabetic portfolio in the U.S. market, leveraging its strong position across multiple therapy areas.
Lupin Limited granted 6,495 stock options to employees at an exercise price of ₹ 2.00 per share. These options, granted under the 2011 ESOP plan, vest over a four-year period starting one year from the grant date.
Lupin Limited received U.S. FDA approval for its generic Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, bioequivalent to Xigduo® XR. The company also secured tentative approval for a 2.5 mg/1,000 mg variant. This regulatory milestone enables Lupin to market the anti-diabetic medication in the United States, expanding its metabolic therapy portfolio.